Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Withdrawn
National Cancer Institute (NCI)
2008-03-24
This clinical trial is studying body mass index in younger patients receiving
prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute
lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory
may help doctors learn more about the affect of body mass index on the way anticancer drugs
work in the body. It may also help doctors predict how patients will respond to treatment
Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia
Withdrawn
Children's Oncology Group
2008-03-24
This clinical trial is studying body mass index in younger patients receiving
prednisone/prednisolone, vincristine, daunorubicin, and pegaspargase for high-risk acute
lymphoblastic leukemia. Studying samples of blood from patients with cancer in the laboratory
may help doctors learn more about the affect of body mass index on the way anticancer drugs
work in the body. It may also help doctors predict how patients will respond to treatment
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Active, not recruiting
National Cancer Institute (NCI)
Phase 2
2017-03-27
This pilot phase II trial studies the side effects of azacitidine and combination
chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs
used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride,
cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium
succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving more than one drug
may kill more cancer cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.